Rajeev M. Shah
Director at Artiva Biotherapeutics, Inc. (ARTV); Director at Hemab Therapeutics Holdings, Inc. (COAG); Director at Mineralys Therapeutics, Inc. (MLYS); Director at Septerna, Inc. (SEPN); 10% Owner at Vor Biopharma Inc. (VOR); Director at Vor Biopharma Inc. (VOR)
Purchase track record
Strong record. Based on 2 purchases with a full 90 days of price history.
Reported trades
| Filed | Stock | Type | Shares | Price | Value | Since |
|---|---|---|---|---|---|---|
| Aug 14SEC | SEPNSepterna, Inc. | Sell | 746,5004,777,415 held (−14%) | $42.50 | $31.7M | -9.7% |
| Aug 14SEC | SEPNSepterna, Inc. | Sell | 746,500725,443 held (−51%) | $42.50 | $31.7M | -9.7% |
| Jul 21SEC | VORVor Biopharma Inc. | Sell | 2134,501,882 held (−0%) | $19.75 | $4K | +0.8% |
| Jul 14SEC | ARTVArtiva Biotherapeutics, Inc. | Buy | 15,10216,811,021 held (+0%) | $8.97 | $135K | -22.6% |
| Jul 14SEC | ARTVArtiva Biotherapeutics, Inc. | Buy | 6,55216,817,573 held (+0%) | $8.94 | $59K | -22.4% |
| May 6SEC | COAGHemab Therapeutics Holdings, Inc. | Buy | 2,541,2506,149,096 held (+70%) | $18.00 | $45.7M | +75.7% |
| May 6SEC | COAGHemab Therapeutics Holdings, Inc. | Buy | 133,750354,938 held (+60%) | $18.00 | $2.4M | +75.7% |
| May 6SEC | COAGHemab Therapeutics Holdings, Inc. | Buy | 87,1436,236,239 held (+1%) | $24.59 | $2.1M | +28.6% |
| May 6SEC | COAGHemab Therapeutics Holdings, Inc. | Buy | 10,2686,246,507 held (+0%) | $25.00 | $257K | +26.5% |
| May 6SEC | COAGHemab Therapeutics Holdings, Inc. | Buy | 14,6116,261,118 held (+0%) | $23.77 | $347K | +33.0% |
| May 6SEC | COAGHemab Therapeutics Holdings, Inc. | Buy | 53,4076,314,525 held (+1%) | $24.83 | $1.3M | +27.3% |
| Apr 24SEC | VORVor Biopharma Inc. | Sell | 165,1502,402,095 held (−6%) | $15.77 | $2.6M | +26.2% |
| Apr 10SEC | VORVor Biopharma Inc. | Sell | 353,2424,202,499 held (−8%) | $16.32 | $5.8M | +21.9% |
| Apr 10SEC | VORVor Biopharma Inc. | Sell | 130,8624,071,637 held (−3%) | $16.91 | $2.2M | +17.7% |
| Apr 10SEC | VORVor Biopharma Inc. | Sell | 135,2013,936,436 held (−3%) | $16.59 | $2.2M | +20.0% |
| Apr 10SEC | VORVor Biopharma Inc. | Sell | 8283,935,608 held (−0%) | $15.75 | $13K | +26.3% |
| Mar 31SEC | MLYSMineralys Therapeutics, Inc. | Buy | 310,7005,767,221 held (+6%) | $23.67 | $7.4M | -1.3% |
| Mar 31SEC | MLYSMineralys Therapeutics, Inc. | Buy | 58,3005,825,521 held (+1%) | $24.16 | $1.4M | -3.3% |
| Oct 17SEC | VORVor Biopharma Inc. | Sell | 42,6991,848,336 held (−2%) | $30.55 | $1.3M | -34.9% |
| Oct 17SEC | VORVor Biopharma Inc. | Sell | 8,38482,882 held (−9%) | $30.55 | $256K | -34.9% |
| Oct 17SEC | VORVor Biopharma Inc. | Sell | 2341,848,102 held (−0%) | $31.17 | $7K | -36.2% |
| Oct 17SEC | VORVor Biopharma Inc. | Sell | 4682,836 held (−0%) | $31.17 | $1K | -36.2% |
| Oct 17SEC | VORVor Biopharma Inc. | Sell | 111,0411,737,061 held (−6%) | $29.32 | $3.3M | -32.1% |
| Oct 17SEC | VORVor Biopharma Inc. | Sell | 21,80461,032 held (−26%) | $29.32 | $639K | -32.1% |
| Oct 17SEC | VORVor Biopharma Inc. | Sell | 15,8261,721,235 held (−1%) | $30.36 | $480K | -34.5% |
| Oct 17SEC | VORVor Biopharma Inc. | Sell | 3,10857,924 held (−5%) | $30.36 | $94K | -34.5% |
| Oct 17SEC | VORVor Biopharma Inc. | Sell | 201,721,215 held (−0%) | $31.35 | $627 | -36.5% |
| Oct 17SEC | VORVor Biopharma Inc. | Sell | 457,920 held (−0%) | $31.35 | $125 | -36.5% |
| Oct 17SEC | VORVor Biopharma Inc. | Sell | 174,5941,546,621 held (−10%) | $29.12 | $5.1M | -31.7% |
| Oct 17SEC | VORVor Biopharma Inc. | Sell | 34,28423,636 held (−59%) | $29.12 | $998K | -31.7% |
| Oct 17SEC | VORVor Biopharma Inc. | Sell | 30,7581,515,863 held (−2%) | $30.28 | $931K | -34.3% |
| Oct 17SEC | VORVor Biopharma Inc. | Sell | 6,04017,596 held (−26%) | $30.28 | $183K | -34.3% |
| Oct 17SEC | VORVor Biopharma Inc. | Sell | 12,6911,503,172 held (−1%) | $31.00 | $393K | -35.8% |
| Oct 17SEC | VORVor Biopharma Inc. | Sell | 2,49215,104 held (−14%) | $31.00 | $77K | -35.8% |
- Sell
Director Rajeev M. Shah sold $31.7M of SEPN at $42.50 — cuts the stake by 51%.
- Buy
Director Rajeev M. Shah bought $135K of ARTV at $8.97 — first open-market purchase in our records.
- Buy
Director Rajeev M. Shah bought $45.7M of COAG at $18.00 — first open-market purchase in our records; raises the stake by 70%.
- Buy
Director Rajeev M. Shah bought $2.4M of COAG at $18.00 — raises the stake by 60%.
- Buy
Director Rajeev M. Shah bought $7.4M of MLYS at $23.67 — first open-market purchase in our records.
- Sell
Director Rajeev M. Shah sold $639K of VOR at $29.32 — cuts the stake by 26%.